Biotechnology company Nanoscope Therapeutics recently announced the formation of Vision Advisory Committee (VAC). 1 VAC is “a group of renowned experts in retina treatment and commercialization,” a ...

Breye Therapeutics announced the successful completion of its phase 1b clinical trial of an oral therapy, danegaptide, for early treatment of non-proliferative diabetic retinopathy (NPDR) and ...

Clinical-stage biotechnology company PYC Therapeutics recently held a type B meeting with the US Food and Drug Administration (FDA) to discuss requirements for a new drug application (NDA) for the ...

Robert Collier said, “success is the sum of small efforts, repeated day in and day out.” So, as we approach the busiest retina meeting season, remember each small effort and give these pearls a try.

Ahead of the Clinical Trials at the Summit (CTS) meeting in Las Vegas, Nevada, Victor Gonzalez, MD, shared an overview of his presentation. Dr. Gonzalez is a trial investigator in the REMAIN follow-up ...

Researchers with the National Institutes of Health (NIH) has identified in a recent study which brain circuits are essential for visual acuity and how they may be affected by retinal cell damage. The ...

In a comprehensive study of geographic atrophy (GA) treatment, Deepak Sambhara, MD, from the Eye Clinic of Wisconsin analyzed long-term patient compliance with two recently FDA-approved complement ...

Biotechnology company Lineage Cell Therapeutics recently announced it will be presenting data from its phase 1/2a clinical study (NCT02286089) at the upcoming Clinical Trials at the Summit (CTS) 2025 ...

Kriya Therapeutics recently announced preclinical data on its gene therapy candidate KRIYA-825, a one-time gene therapy delivered by suprachoroidal injection, for the treatment of geographic atrophy ...

Ashvattha Therapeutics recently announced positive interim phase 2 results for migaldendranib (MGB). 1 MGB is described as a novel subcutaneously administered nanomedicine for the treatment of retinal ...

Alkeus Pharmaceuticals, Inc., announced additional data from its Phase 2 clinical SAGA study in geographic atrophy (GA) secondary to age-related macular degeneration (AMD). In this trial patients ...

Investigators from the Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, led by Ying Zhu, MD, PhD, who studied the ocular effects of repeated intravitreal ...